Regulus Therapeutics Inc. (NASDAQ:RGLS) was down -0.59% (0) to $0.9 and showed a volume of 0.88 mln shares. It has ranged in price between $0.853-$0.94 after having started the session at $0.9 as compared to the previous trading day’s close of $0.9. The GAP was therefore 0%. The firm’s stock has a market capitalization of $87.69 mln.
The analysts offering 12 month price targets for Regulus Therapeutics Inc. have a median target of $1.33, with a high estimate of $4 and a low estimate of $1. The median estimate represents a 47.78% increase from the last price.
According to Zacks brokerage recommendations, Regulus Therapeutics Inc. (NASDAQ:RGLS)’s Buy count is 0 and Strong Buy is 2 while the number of analysts recommending Sell and Strong Sell are 0 and 5, respectively. Also, the Hold rating count is 0, as of 10 Aug 2017. The analyst recommendations from a month ago are 0 Buy, 3 Strong Buy, 0 Sell, 0 Hold and 3. Strong Sell. Investors might also notice that two months ago the Buy recommendations (0) were less than Sell recommendations (0). The count of Hold ratings in that period was 0. Chicago-based equity research firm Zacks Investment Research has assigned this stock ABR (Average Brokerage Recommendation) of 2.43, suggesting the market has given up on the stock.
Now, the FactSet Research estimate calls for Q3 2017 earnings of US$-0.18. A month ago, analyst EPS consensus estimated earnings of US$-0.27 per share. They were forecasting US$-0.28 per share three months ago. The Q4 2017 consensus earnings estimates for the company have stabilized at US$-0.18 per share. A month ago, they told us to expect earnings of US$-0.28 per share while three months ago their EPS consensus estimate was US$-0.3.
Regulus Therapeutics Inc. (NASDAQ:RGLS) tumbled -60.21% year-to-date. The shares have slowed down in recent weeks, with their price down about -42.25% in the past three months. RGLS fell -4.62%, plunged -7.17% and sank -28.38% in the week, one month and six months, respectively. The most recent short interest data show 7.85% of the company’s stock are short sold. It would take about 2.79 days to cover all short positions. In terms of volatility, it has a beta coefficient of 1.61 and technical analysis volatility indicator called Average True Range or ATR around 0.09.
Regulus Therapeutics Inc. (RGLS) closed -46.86% below its 200-day moving average and is -16.59% below another chart threshold, its 50-day moving average. The stock stands nearly -75.9% off versus the 52-week high and 4.04% away from the 52-week low. The number of shares currently owned by investors are 97.96 mln.